Ongoing drug shortages are repeatedly blamed for contributing to rising prices, but a new analysis suggested that prices rose not only substantially, but twice as fast, for medicines that were in short supply than if there were no shortages for those treatments.
Specifically, in the 11 months after a shortage began, the expected price increase for all drugs in short supply was, on average, 20 percent compared with a 9 percent average price hike in the absence of a shortage, according to the analysis in the Annals of Internal Medicine.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
